Bayer and Onyx initiate pivotal phase III clinical trial in kidney cancer.

Reports that Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals have begun in 2003 an international, multi-center phase III trial to further evaluate the safety and efficacy of the investigational drug BAY 43-9006, a novel signal transduction inhibitor, in the treatment of advanced renal cell carcinoma. Key issues of interest; Analysis of pertinent topics and relevant issues; Implications on cancer research.